Where are we in the pandemic?
The bottom line here is that anyone making the statement ‘coming out of the Covid environment’ has not kept up with the data, which demonstrate the following:
(more…)Posts Tagged ‘SARS-CoV-2’
Over? It hasn’t even started!
Posted in Biochemistry, Covid-19, Research integrity, Science process, Scientific progress, Universities, tagged covid19, Long Covid, research, SARS-CoV-2, science, Science progress on July 12, 2022|
Heparin inhibits SARS-cov-2 cell infectivity
Posted in Biochemistry, Covid-19, Glycobiology, Scientific progress, Viruses, tagged Coronaviruses, heparan sulfate, heparin, SARS-CoV-2, science on April 29, 2020|
With new data in hand, our first preprint on SARS-cov-2 receptor binding domain (RBD) interacting with heparin now has a sibling, which demonstrates that heparin inhibits the infection of Vero cells by SARS-cov-2
Some of the key points of the team’s new work are:
- Inhibition of viral infectivity in a Vero cell model by heparin, which is a better inhibitor for SARS-cov-2 than SARS-cov.
- Analysis of the interactions of a more extended library of model heparins with the SARS-cov-2 receptor binding domain. As with many other heparin-binding proteins, these data show that while sulfation is critical for RBD binding, the amount of sulfate is not, but instead it is the spatial arrangement of sulfate groups that is most important.
Together the data point to heparin being a potentially useful therapeutic to reduce infectivity. (more…)
The 2019 coronavirus (SARS-CoV-2) surface protein (Spike) S1 Receptor Binding Domain undergoes conformational change upon heparin binding
Posted in Biochemistry, Glycobiology, Science process, Scientific progress, Viruses, tagged heparan sulphate, heparin, research, SARS-CoV-2, science, Universities on March 3, 2020| 1 Comment »
Thursday last week (Feb 27) Mark was up from Keele and popped his head around my office door – not a surprise, as he is often here to do circular dichroism on various heparin-binding proteins – to announce that Marcelo had managed to make some SARS-CoV-2 S1 receptor binding domain. Mark had asked Hao, my postdoc, to do some SPR measurements to see if it bound heparin.
Later in the day I went over to the SPR/CD lab to find Courtney, Mark’s PhD student and Mark beavering away on the CD. A quick discussion. Hao had finished some work on our first grade A heparin functionalised SPR surface, so we set about injecting the SARS-CoV-2 surface protein (Spike) S1 Receptor Binding Domain – a one shot experiment, as amounts of protein were limited, so we injected 1 mL at 500 µL/min (I like high flow rates as mixing is way better, though still far from perfect).
Bingo. (more…)
Ferniglab Blog 